前列腺癌的医学管理新进展。
New developments in the medical management of prostate cancer.
机构信息
Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
出版信息
Mayo Clin Proc. 2010 Jan;85(1):77-86. doi: 10.4065/mcp.2009.0442.
Abstract
Prostate cancer is a substantial public health burden and a leading cause of cancer-related morbidity and mortality in the United States despite the observation that annual prostate cancer-specific mortality rates have been declining during the previous decade. Although the reasons for this positive development are unclear, a combination of factors may have contributed. This update will review ongoing developments and summarize therapeutic advances in prostate cancer treatment on the basis of the current understanding of prostate cancer biology. Literature for this review was selected in 2009 by searching PubMed for the following keywords: prostatic neoplasms, castration, androgen receptor, hormonal, and chemotherapy. Emphasis is placed on published clinical studies in advanced prostate cancer therapeutics in the past 5 to 10 years. Also included in the review are novel hormonal agents targeting the androgen receptor currently in development for the treatment of advanced prostate cancer.
摘要
前列腺癌是美国重大的公共卫生负担，也是导致癌症发病率和死亡率的主要原因，尽管在此前十年中观察到前列腺癌特异性死亡率呈下降趋势。尽管目前尚不清楚这种积极趋势的原因，但可能有多种因素共同作用。本更新将根据目前对前列腺癌生物学的理解，回顾正在进行的研究进展，并总结前列腺癌治疗方面的治疗进展。本综述的文献资料于 2009 年通过在 PubMed 上搜索以下关键词进行选择：前列腺肿瘤，去势，雄激素受体，激素和化疗。重点是过去 5 到 10 年中晚期前列腺癌治疗的已发表临床研究。本综述还包括目前正在开发用于治疗晚期前列腺癌的针对雄激素受体的新型激素药物。
相似文献
1
New developments in the medical management of prostate cancer.前列腺癌的医学管理新进展。
Mayo Clin Proc. 2010 Jan;85(1):77-86. doi: 10.4065/mcp.2009.0442.
2
[The treatment of castration-resistant prostate cancer].[去势抵抗性前列腺癌的治疗]
Magy Onkol. 2012 Dec;56(4):219-28. Epub 2012 Oct 3.
3
The utility of prostate-specific antigen in the management of advanced prostate cancer.前列腺特异性抗原在晚期前列腺癌治疗中的应用。
BJU Int. 2013 Sep;112(5):548-60. doi: 10.1111/bju.12061. Epub 2013 Jul 4.
4
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.局部晚期和转移性前列腺癌的系统治疗进展：精准肿瘤学时代下转移性去势抵抗性前列腺癌的管理。
Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.
5
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.前列腺特异性抗原对延迟联合雄激素阻断治疗的反应预测了去势抵抗性前列腺癌患者后续雌激素和多西他赛治疗后的生存。
BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.
6
Overcoming castration resistance in prostate cancer.克服前列腺癌的去势抵抗。
Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b.
7
Treatment options in hormone-refractory prostate cancer: current and future approaches.激素难治性前列腺癌的治疗选择：当前与未来的方法
Drugs. 2001;61(15):2177-92. doi: 10.2165/00003495-200161150-00003.
8
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.雄激素受体靶向治疗前列腺癌：抗雄激素治疗 35 年的进展。
J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3.
9
Novel concepts in androgen receptor blockade.雄激素受体阻断的新概念
Cancer J. 2008 Jan-Feb;14(1):11-4. doi: 10.1097/PPO.0b013e318161d13e.
10
[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].[前列腺癌与新的激素治疗：作用机制及主要临床结果]
Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7.
引用本文的文献
1
Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.遗传性DNA修复基因突变对激素敏感性和去势抵抗性转移性前列腺癌的贡献及其对临床结局的影响
JCO Precis Oncol. 2019 Sep 17;3. doi: 10.1200/PO.19.00067. eCollection 2019.
2
Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer.基于血液的蛋白质组学在癌症临床应用中的挑战与机遇
Cancers (Basel). 2020 Aug 27;12(9):2428. doi: 10.3390/cancers12092428.
3
[Citron Rho-interacting serine/threonine kinase knockdown suppresses prostate cancer cell proliferation and metastasis by blocking Hippo-YAP pathway].[西特隆Rho相互作用丝氨酸/苏氨酸激酶敲低通过阻断Hippo-YAP通路抑制前列腺癌细胞增殖和转移]
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Mar 30;39(3):257-263. doi: 10.12122/j.issn.1673-4254.2019.03.01.
4
Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.SOX9、Wnt/β-连环蛋白和雄激素受体信号在去势抵抗性前列腺癌中的相互作用。
Int J Mol Sci. 2019 Apr 26;20(9):2066. doi: 10.3390/ijms20092066.
5
Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells.细胞分裂周期蛋白 20（CDC20）通过稳定癌症干细胞样细胞中的β-连环蛋白促进前列腺癌进展。
EBioMedicine. 2019 Apr;42:397-407. doi: 10.1016/j.ebiom.2019.03.032. Epub 2019 Mar 21.
6
Targeting DNA Methyltranferases in Urological Tumors.靶向泌尿肿瘤中的DNA甲基转移酶
Front Pharmacol. 2018 Apr 13;9:366. doi: 10.3389/fphar.2018.00366. eCollection 2018.
7
Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.抑制 Wnt/β-连环蛋白通路克服去势抵抗性前列腺癌对恩杂鲁胺的耐药性。
Cancer Res. 2018 Jun 15;78(12):3147-3162. doi: 10.1158/0008-5472.CAN-17-3006. Epub 2018 Apr 26.
8
9
Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.醋酸阿比特龙或恩杂鲁胺治疗的前列腺癌患者的治疗持续时间。
J Manag Care Spec Pharm. 2017 Feb;23(2):225-235. doi: 10.18553/jmcp.2016.16233. Epub 2016 Dec 7.
10
Epigenetic modulators as therapeutic targets in prostate cancer.表观遗传调节剂作为前列腺癌的治疗靶点
Clin Epigenetics. 2016 Sep 15;8:98. doi: 10.1186/s13148-016-0264-8. eCollection 2016.
本文引用的文献
1
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.醋酸阿比特龙对CYP17的选择性抑制在去势抵抗性前列腺癌的治疗中具有高度活性。
J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.
2
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.TMPRSS2-ERG的协同作用与PI3激酶通路激活在前列腺癌发生中的作用
Nat Genet. 2009 May;41(5):524-6. doi: 10.1038/ng.371. Epub 2009 Apr 26.
3
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.开发用于治疗晚期前列腺癌的第二代抗雄激素药物。
Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9.
4
Screening and prostate-cancer mortality in a randomized European study.一项欧洲随机研究中的筛查与前列腺癌死亡率
N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.
5
Mortality results from a randomized prostate-cancer screening trial.一项前列腺癌随机筛查试验的死亡率结果。
N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18.
6
CYP17 inhibition as a hormonal strategy for prostate cancer.CYP17抑制作为前列腺癌的一种激素治疗策略。
Nat Clin Pract Urol. 2008 Nov;5(11):610-20. doi: 10.1038/ncpuro1237.
7
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.局限性前列腺癌根治性前列腺切除术与观察等待治疗的比较：斯堪的纳维亚前列腺癌研究组-4随机试验
J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54. doi: 10.1093/jnci/djn255. Epub 2008 Aug 11.
8
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.CYP17选择性抑制剂醋酸阿比特龙的I期临床试验证实，去势抵抗性前列腺癌通常仍由激素驱动。
J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21.
9
Targeting CYP17: established and novel approaches in prostate cancer.靶向细胞色素P450 17α羟化酶：前列腺癌的既定方法与新方法
Curr Opin Pharmacol. 2008 Aug;8(4):449-57. doi: 10.1016/j.coph.2008.06.004. Epub 2008 Jul 28.
10
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.转移性前列腺癌中瘤内雄激素的维持：去势抵抗性肿瘤生长的一种机制。
Cancer Res. 2008 Jun 1;68(11):4447-54. doi: 10.1158/0008-5472.CAN-08-0249.
Zotero 插件